Fennec Pharmaceuticals Inc.
PEDMARK
cisplatin-induced hearing loss
Resolved
218days ago
Phase 3 readout · Dec 1, 2025
What's at stake
Phase 3 trial results for PEDMARK in cisplatin-induced hearing loss are due Dec 1, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In December, Fennec announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) ”